Recombinant oncolytic virus NDV-anti-VEGFR2 enhances radiotherapy sensitivity in NSCLC by targeting VEGF signaling and impairing DNA repair

No abstract is available for this paper.

• Publication year

  2025

• Venue

  Gene Therapy

• Publication date

  2025-05-17

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1038/s41434-025-00540-xPMID 40382521
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The Application of Newcastle Disease Virus (NDV): Vaccine Vectors and Tumor Therapy

  2024cited by this paper
• Hypoxia Modulates Radiosensitivity and Response to Different Radiation Qualities in A549 Non-Small Cell Lung Cancer (NSCLC) Cells

  2024cited by this paper
• Angiogenic signaling pathways and anti-angiogenic therapy for cancer

  2023cited by this paper
• Radiation combined with oncolytic vaccinia virus provides pronounced antitumor efficacy and induces immune protection in an aggressive glioblastoma model.

  2023cited by this paper
• DC101, an anti-VEGFR2 agent, promotes high-endothelial venule formation and immune infiltration versus SAR131675 and fruquintinib.

  2023cited by this paper
• Mechanisms and applications of radiation-induced oxidative stress in regulating cancer immunotherapy

  2023cited by this paper
• An oncolytic virus as a promising candidate for the treatment of radioresistant oral squamous cell carcinoma

  2022cited by this paper
• H2AX mRNA expression reflects DNA repair, cell proliferation, metastasis, and worse survival in breast cancer.

  2022cited by this paper
• Hypoxia-Inducible Factor-1: A Novel Therapeutic Target for the Management of Cancer, Drug Resistance, and Cancer-Related Pain

  2022cited by this paper
• Non‐small cell lung cancer in China

  2022cited by this paper
• Neutralization of the induced VEGF-A potentiates the therapeutic effect of an anti-VEGFR2 antibody on gastric cancer in vivo

  2021cited by this paper
• RETRACTED: Oncolytic virotherapy promotes radiosensitivity in soft tissue sarcoma by suppressing anti-apoptotic MCL1 expression

  2021cited by this paper
• VEGFR2 activity on myeloid cells mediates immune suppression in the tumor microenvironment

  2021cited by this paper
• Oncolytic Newcastle disease virus expressing the co-stimulator OX40L as immunopotentiator for colorectal cancer therapy

  2021cited by this paper
• Apatinib inhibits the growth of small cell lung cancer via a mechanism mediated by VEGF, PI3K/Akt and Ki‐67/CD31

  2021cited by this paper
• Normalizing Tumor Vasculature to Reduce Hypoxia, Enhance Perfusion, and Optimize Therapy Uptake

  2021cited by this paper
• The Multifaceted Role of Macrophages in Oncolytic Virotherapy

  2021cited by this paper
• Newcastle disease virus expressing an angiogenic inhibitor exerts an enhanced therapeutic efficacy in colon cancer model

  2021cited by this paper
• Radiation Therapy in Non-Small-Cell Lung Cancer.

  2021cited by this paper
• γ-H2AX as a potential indicator of radiosensitivity in colorectal cancer cells

  2020cited by this paper
• Tumor Hypoxia: Impact on Radiation Therapy and Molecular Pathways

  2020cited by this paper
• Efficacy of Combination Chemotherapy Using a Novel Oral Chemotherapeutic Agent, FTD/TPI, with Ramucirumab Murine Version DC101 in a Mouse Syngeneic Cancer Transplantation Model

  2020cited by this paper
• Inside the hypoxic tumour: reprogramming of the DDR and radioresistance

  2020cited by this paper
• Therapeutic potential of anti-VEGF receptor 2 therapy targeting for M2-tumor-associated macrophages in colorectal cancer

  2020cited by this paper
• Oncolytic Newcastle disease virus expressing a checkpoint inhibitor as a radioenhancing agent for murine melanoma

  2019influential reference
• Cytochalasin H Inhibits Angiogenesis via the Suppression of HIF-1α Protein Accumulation and VEGF Expression through PI3K/AKT/P70S6K and ERK1/2 Signaling Pathways in Non-Small Cell Lung Cancer Cells

  2019cited by this paper
• STING activation reprograms tumor vasculatures and synergizes with VEGFR2 blockade.

  2019cited by this paper
• Hypoxia inducible factor‐1α/vascular endothelial growth factor signaling activation correlates with response to radiotherapy and its inhibition reduces hypoxia‐induced angiogenesis in lung cancer

  2018cited by this paper
• VEGF may contribute to macrophage recruitment and M2 polarization in the decidua

  2018cited by this paper
• Targeting VEGFR2 with Ramucirumab strongly impacts effector/ activated regulatory T cells and CD8+ T cells in the tumor microenvironment

  2018cited by this paper
• Targeting the vasculature of tumours: combining VEGF pathway inhibitors with radiotherapy.

  2018cited by this paper
• Progress and prospects of early detection in lung cancer

  2017cited by this paper
• Combining Oncolytic Adenovirus with Radiation—A Paradigm for the Future of Radiosensitization

  2017cited by this paper
• Phosphorylated fraction of H2AX as a measurement for DNA damage in cancer cells and potential applications of a novel assay

  2017cited by this paper
• Proinflammatory response induced by Newcastle disease virus in tumor and normal cells

  2017cited by this paper
• VEGF-A/VEGFR2 signaling network in endothelial cells relevant to angiogenesis

  2016cited by this paper
• Interaction between hypoxia, AKT and HIF-1 signaling in HNSCC and NSCLC: implications for future treatment strategies

  2016cited by this paper
• Antagonist antibodies to vascular endothelial growth factor receptor 2 (VEGFR-2) as anti-angiogenic agents.

  2016cited by this paper
• Endostatin exerts radiosensitizing effect in non-small cell lung cancer cells by inhibiting VEGFR2 expression

  2015cited by this paper
• Preclinical Testing Oncolytic Vaccinia Virus Strain GLV-5b451 Expressing an Anti-VEGF Single-Chain Antibody for Canine Cancer Therapy

  2015cited by this paper
• Oncolytic viruses: a new class of immunotherapy drugs

  2015cited by this paper
• The tumour microenvironment after radiotherapy: mechanisms of resistance and recurrence

  2015cited by this paper
• Therapeutic Implications for Overcoming Radiation Resistance in Cancer Therapy

  2015cited by this paper
• Viral concentration determination through plaque assays: using traditional and novel overlay systems.

  2014cited by this paper
• Oncolytic Newcastle disease virus for cancer therapy: old challenges and new directions.

  2012cited by this paper
• The VEGF pathway in cancer and disease: responses, resistance, and the path forward.

  2012cited by this paper
• Effect of recombinant human endostatin on radiosensitivity in patients with non-small-cell lung cancer.

  2012cited by this paper
• Hypoxic modification of radiotherapy in squamous cell carcinoma of the head and neck--a systematic review and meta-analysis.

  2011cited by this paper
• How can we overcome tumor hypoxia in radiation therapy?

  2011cited by this paper
• Normalization of the vasculature for treatment of cancer and other diseases.

  2011cited by this paper
• Strategies to improve radiotherapy with targeted drugs

  2011cited by this paper
• PI3K/AKT/mTOR Pathway in Angiogenesis

  2011cited by this paper
• Oncolytic viruses in radiation oncology.

  2011cited by this paper
• VEGF receptor 2/-3 heterodimers detected in situ by proximity ligation on angiogenic sprouts

  2010cited by this paper
• The VEGF pathway and the AKT/mTOR/p70S6K1 signalling pathway in human epithelial ovarian cancer

  2009cited by this paper
• The consequences of Rad51 overexpression for normal and tumor cells.

  2008cited by this paper
• Human tumor xenografts recurring after radiotherapy are more sensitive to anti-vascular endothelial growth factor receptor-2 treatment than treatment-naive tumors.

  2007cited by this paper
• Divergent activities of an engineered antibody in murine and human systems have implications for therapeutic antibodies

  2006cited by this paper
• Combined vascular endothelial growth factor-targeted therapy and radiotherapy for rectal cancer: theory and clinical practice.

  2006cited by this paper
• Angiogenesis and radiation response modulation after vascular endothelial growth factor receptor-2 (VEGFR2) blockade.

  2005cited by this paper
• Radiation activates HIF-1 to regulate vascular radiosensitivity in tumors: role of reoxygenation, free radicals, and stress granules.

  2004cited by this paper
• Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoietin-1, and matrix metalloproteinases.

  2004cited by this paper
• Intratumoral hypoxia, radiation resistance, and HIF-1.

  2004cited by this paper
• Pretreatment oxygenation predicts radiation response in advanced squamous cell carcinoma of the head and neck.

  1996cited by this paper

• Oncolytic virus therapy for glioma: current clinical trials and overcoming key obstacles.

  2025cites this paper
• Engineering the tumor microenvironment: oncolytic NDV to facilitate CAR-T cell therapy

  2025cites this paper
• Research progress on recombinant NDV in cancer therapy

  2025cites this paper